¼¼°èÀÇ ¹Ì»ý¹° ºÐ¼®±â ½ÃÀå
Microbiology Analyzers
»óǰÄÚµå : 1793034
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 390 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,183,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,550,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ¹Ì»ý¹° ºÐ¼®±â ½ÃÀåÀº 2030³â±îÁö 12¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 9¾ï 5,320¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¹Ì»ý¹° ºÐ¼®±â ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 4.4%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 12¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ÀÚµ¿ ºÐ¼®±â´Â CAGR 3.6%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 5¾ï 5,860¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÓ»ó ºÐ¼®±â ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 3.9%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 2¾ï 5,970¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR6.8%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¹Ì»ý¹° ºÐ¼®±â ½ÃÀåÀº 2024³â¿¡ 2¾ï 5,970¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 6.8%·Î ¼ºÀåÇÏ¿© 2030³â±îÁö 2¾ï 3,800¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 2.1%¿Í 4.4%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.7%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ ¹Ì»ý¹° ºÐ¼®±â ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¹Ì»ý¹° ºÐ¼®±â´Â ÀÓ»ó ¹× Áø´Ü ¹Ì»ý¹°Çп¡ ¾î¶² Çõ¸íÀ» ºÒ·¯ÀÏÀ¸Å°°í Àִ°¡?

¹Ì»ý¹° ºÐ¼®±â´Â ½ÇÇè½Ç¿¡¼­ °¨¿°, ½Äǰ ¿À¿°, ȯ°æ À§ÇèÀ» À¯¹ßÇÏ´Â ¹Ì»ý¹°À» °¨Áö, ½Äº°, ¸ð´ÏÅ͸µÇÏ´Â ¹æ½ÄÀ» º¯È­½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ ÀÚµ¿È­ ½Ã½ºÅÛÀº ¹ÚÅ׸®¾Æ, ¹ÙÀÌ·¯½º, °õÆÎÀÌ, ±â»ýÃæ¿¡ ´ëÇÑ ½Å¼ÓÇϰí Á¤È®ÇÑ °í󸮷® ºÐ¼®À» Á¦°øÇϸç, ¹è¾ç ±â¹Ý ¹æ¹ý¿¡ ÇÊ¿äÇÑ Ã³¸® ½Ã°£À» ´ÜÃàÇÕ´Ï´Ù. ÀÓ»ó ÇöÀå¿¡¼­ ¹Ì»ý¹° ºÐ¼®±â´Â º¸´Ù ½Å¼ÓÇÑ º´¿ø±Õ °ËÃâ°ú Ç×»ýÁ¦ °¨¼ö¼º °Ë»ç¸¦ °¡´ÉÇÏ°Ô ÇÔÀ¸·Î½á Ç÷·ù °¨¿°, È£Èí±â Áúȯ, ¿ä·Î °¨¿°, º´¿ø ³» °¨¿°ÀÇ Áø´Ü¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. °í±Þ ºÐ¼®±â¿¡´Â MALDI-TOF Áú·®ºÐ¼®, ÇÙ»ê ÁõÆø, ½Ç½Ã°£ ÁßÇÕÈ¿¼Ò ¿¬¼â¹ÝÀÀ(PCR) µîÀÇ ±â¼úÀÌ ³»ÀåµÇ¾î ÀÖ¾î, ½ÇÇè½ÇÀº ±âº»ÀûÀÎ µ¿Á¤»Ó¸¸ ¾Æ´Ï¶ó ¹Ì»ý¹°ÀÇ À¯ÀüÀû Ư¼º ºÐ¼®±îÁö ÇÒ ¼ö ÀÖ½À´Ï´Ù. ½ÇÇè½Ç Á¤º¸ ½Ã½ºÅÛ(LIS)°úÀÇ ÅëÇÕÀº ¿øÈ°ÇÑ µ¥ÀÌÅÍ °ü¸®, ÃßÀû¼º, º¸°í¸¦ Áö¿øÇÏ¿© ¾÷¹« È¿À²¼ºÀ» ´õ¿í Çâ»ó½Ãŵ´Ï´Ù. ¶ÇÇÑ, ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº ¼öÀÛ¾÷À» ÁÙÀ̰í ÀÎÀ§ÀûÀÎ ½Ç¼öÀÇ À§ÇèÀ» ÃÖ¼ÒÈ­ÇÕ´Ï´Ù. ÀÌ´Â ´ë·® °Ë»ç½ÇÀ̳ª Áý´Ü ¹ßº´ ½Ã³ª¸®¿À¿¡¼­ ƯÈ÷ Áß¿äÇÕ´Ï´Ù. ¶ÇÇÑ, ¹Ì»ý¹° ºÐ¼®±â´Â ÄÄÆÑÆ®ÇÑ µðÀÚÀΰú »ç¿ëÀÚ Ä£È­ÀûÀÎ ÀÎÅÍÆäÀ̽º·Î ÀÎÇØ Áø·á¼Ò, À̵¿Çü °Ë»ç½Ç, ÇöÀå Áø·á¼Ò µî ºÐ»êµÈ ȯ°æ¿¡¼­ »ç¿ëÇϱ⿡ ÀûÇÕÇÕ´Ï´Ù. Ç×±ÕÁ¦ ³»¼º(AMR)ÀÌ Áö¼ÓÀûÀ¸·Î Áõ°¡Çϰí ÀÖ´Â °¡¿îµ¥, ÀÌ·¯ÇÑ ½Å¼Ó Áø´Ü µµ±¸´Â ÀûÀýÇÑ Ä¡·á¿Í °¨¿° ´ëÃ¥À» ¸¶·ÃÇÏ´Â µ¥ ÇʼöÀûÀÎ µµ±¸°¡ µÇ°í ÀÖ½À´Ï´Ù. ½Äǰ ¾ÈÀü ¹× Á¦¾à ȸ»çµµ ¿ø·á ¹× ÃÖÁ¾ Á¦Ç°¿¡¼­ ¿À¿° ¹°ÁúÀ» °¨ÁöÇÏ¿© ¾ö°ÝÇÑ Ç°Áú º¸Áõ ±âÁØÀ» ÃæÁ·Çϱâ À§ÇØ ÀÌ·¯ÇÑ ½Ã½ºÅÛ¿¡ ÀÇÁ¸Çϰí ÀÖ½À´Ï´Ù. ÀÀ¿ë ºÐ¾ßÀÇ È®´ë¿Í Áö¼ÓÀûÀÎ ±â¼ú °³¼±À¸·Î ¹Ì»ý¹° ºÐ¼®±â´Â Çö´ë Áø´Ü ¹× °øÁß º¸°Ç ¸ð´ÏÅ͸µÀÇ ÇÙ½ÉÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù.

ÀÚµ¿È­¿¡ ´ëÇÑ ¼ö¿ä°¡ ¹Ì»ý¹° ºÐ¼®±âÀÇ ±â¼ú Çõ½ÅÀ» ÃËÁøÇÏ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

½ÇÇè½Ç ÀÚµ¿È­¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ¹Ì»ý¹° ºÐ¼®±âÀÇ ±â¼ú Çõ½Å°ú ÅõÀÚ¸¦ ÃËÁøÇÏ´Â Å« ÈûÀÌ µÇ°í ÀÖ½À´Ï´Ù. ½ÇÇè½ÇÀº Áõ°¡ÇÏ´Â ½Ã·á·®, Á¦ÇÑµÈ ÀηÂ, ´õ ºü¸¥ °á°úÀÇ Çʿ伺¿¡ Á÷¸éÇϰí ÀÖÀ¸¸ç, ÀÚµ¿È­ ½Ã½ºÅÛÀº ÃÖ¼ÒÇÑÀÇ Àη °³ÀÔÀ¸·Î ¸ÅÀÏ ¼ö¹é °³ÀÇ ½Ã·á¸¦ ó¸®ÇÒ ¼ö ÀÖ´Â ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ÀÚµ¿È­´Â ½Ã·áÀÇ Ç÷¹ÀÌÆ®, ¹è¾ç, ÄÝ·Î´Ï Ä«¿îÆÃ, µ¿Á¤ µî ±âÁ¸ ¹Ì»ý¹°ÇÐ ¿öÅ©Ç÷οìÀÇ ÁÖ¿ä º´¸ñÇö»óÀ» ÇØ°áÇØÁÝ´Ï´Ù. ÀΰøÁö´É ¹× ¸Ó½Å·¯´× ¾Ë°í¸®Áò°ú ÅëÇÕµÈ Á¤±³ÇÑ ·Îº¿ ½Ã½ºÅÛÀ» ÅëÇØ ¹Ì»ý¹° Áõ½ÄÀÇ ½Ç½Ã°£ À̹ÌÁö ºÐ¼®, °Ë»ç °á°úÀÇ ÀÚµ¿ ÇØ¼®, ¹ßº´ ¸ð´ÏÅ͸µÀ» À§ÇÑ ¿¹Ãø ºÐ¼®ÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº Áø´Ü Áֱ⸦ Å©°Ô ´ÜÃàÇϰí ÁßȯÀÚ Ä¡·á ½Ã³ª¸®¿À¿¡¼­ ÀÇ»ç°áÁ¤À» °³¼±ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¿ÏÀü ÀÚµ¿È­ ½Ã½ºÅÛÀº 󸮷®À» Çâ»ó½Ãų »Ó¸¸ ¾Æ´Ï¶ó ÀÓ»ó ÀÎÁõ ¹× ±ÔÁ¦ Áؼö¿¡ ÇʼöÀûÀÎ Àϰü¼º°ú ¹Ýº¹¼ºÀ» º¸ÀåÇÕ´Ï´Ù. ¶ÇÇÑ, Â÷¼¼´ë ºÐ¼®±â´Â ¸ðµâ½Ä ¹× È®Àå °¡´ÉÇϵµ·Ï ¼³°èµÇ¾î ±âÁ¸ ÀÎÇÁ¶ó¸¦ »õ·Ó°Ô ±¸ÃàÇÏÁö ¾Ê°íµµ ½ÇÇè½ÇÀÇ ±â´ÉÀ» È®ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÚµ¿È­¸¦ ÅëÇÑ Áø´Ü ÇÁ·Î¼¼½ºÀÇ Ç¥ÁØÈ­´Â ÀÓ»ó ȯ°æ¿¡¼­ÀÇ ±³Â÷ ¿À¿°À» ÁÙÀÌ°í »ý¹°ÇÐÀû ¾ÈÀü¼ºÀ» Çâ»ó½Ã۴µ¥µµ µµ¿òÀÌ µË´Ï´Ù. ÀÚµ¿È­´Â ÀÚ¿øÀÌ ºÎÁ·ÇÑ È¯°æ¿¡¼­ ƯÈ÷ Å« È¿°ú¸¦ ¹ßÈÖÇÏ¿© Àη ºÎÁ·À» º¸¿ÏÇÏ°í °íǰÁú Áø´Ü¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» Çâ»ó½Ãŵ´Ï´Ù. º´¿ø°ú Áø´Ü ½ÇÇè½Ç°¡ È¿À²¼ºÀ» ÃÖÀûÈ­ÇÏ°í ¿î¿µ ºñ¿ëÀ» Àý°¨Çϱâ À§ÇØ ¸° °æ¿µ ¿øÄ¢À» äÅÃÇÔ¿¡ µû¶ó ÀÚµ¿È­µÈ ¹Ì»ý¹° ºÐ¼®±âÀÇ ¿ªÇÒÀÌ ´õ¿í Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù. ÀÚµ¿È­¿Í Ŭ¶ó¿ìµå ±â¹Ý µ¥ÀÌÅÍ °ü¸® ¹× µðÁöÅÐ ¿¬°áÀÇ À¶ÇÕÀº ÅëÇÕ Áø´Ü ¹× ¿ø°Ý °á°ú °øÀ¯µµ Áö¿øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ °³¹ßÀº ½ÇÇè½Ç ¿öÅ©Ç÷ο츦 À籸¼ºÇÒ »Ó¸¸ ¾Æ´Ï¶ó, ½Å¼ÓÇϰí Á¤È®ÇÑ µ¥ÀÌÅÍ ±â¹Ý ¹Ì»ý¹° Áø´ÜÀÇ »õ·Î¿î ½Ã´ë¸¦ ¿­¾î°¡°í ÀÖ½À´Ï´Ù.

»õ·Î¿î °¨¿°º´ À§Çù°ú ¼¼°è º¸°ÇÀÇ ¿ì¼±¼øÀ§°¡ ¾î¶»°Ô ½ÃÀå ¼ö¿ä¸¦ ÃËÁøÇϰí Àִ°¡?

»õ·Î¿î Àü¿°º´ÀÇ ÃâÇö°ú ÀÌÀü¿¡ ÅëÁ¦µÇ¾ú´ø º´¿ø±ÕÀÇ ºÎȰÀº ¹Ì»ý¹° ºÐ¼®±â¿¡ ´ëÇÑ Àü ¼¼°è ¼ö¿ä¸¦ °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. Äڷγª19 ÆÒµ¥¹ÍÀº ´Ù¾çÇÑ È¯°æ¿¡¼­ È®Àå °¡´ÉÇÏ°í ½Å·ÚÇÒ ¼ö ÀÖ´Â ½Å¼ÓÇÑ Áø´Ü ½Ã½ºÅÛÀÇ Á߿伺À» ºÎ°¢½ÃÄ×½À´Ï´Ù. ºÐÀÚ ¹× ¹è¾ç ±â¹Ý ºÐ¼®ÀÌ °¡´ÉÇÑ ¹Ì»ý¹° ºÐ¼®±â´Â °Ë»ç Àü·«¿¡¼­ ¸Å¿ì Áß¿äÇϸç, ÀÏ»óÀûÀÎ Áø´Ü°ú ±ä±Þ ´ëÀÀ ½Ã³ª¸®¿À ¸ðµÎ¿¡¼­ À¯¿ëÇÏ´Ù´Â Á¡ÀÌ °­Á¶µÇ¾ú½À´Ï´Ù. º¸°Ç ½Ã½ºÅÛÀÌ ÇâÈÄ Àü¿°º´ ¹ß»ý¿¡ ´ëºñÇϱâ À§ÇØ °¨½Ã ÀÎÇÁ¶ó¸¦ °­È­ÇÔ¿¡ µû¶ó °øÁß º¸°Ç ¿¬±¸¼Ò, ¹Î°£ Ŭ¸®´Ð, ±¹°æ °ü¸® ½Ã¼³¿¡¼­ ÷´Ü ¹Ì»ý¹° ºÐ¼®±â¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. °áÇÙ, µ¶°¨, ¼ºº´°ú °°Àº Áúº´Àº ƯÈ÷ ÁßÀú¼Òµæ ±¹°¡¿¡¼­ Áö¼ÓÀûÀ¸·Î ½É°¢ÇÑ °Ç°­ ºÎ´ãÀ» ¾ß±âÇϰí ÀÖÀ¸¸ç, ½Å¼ÓÇϰí Á¤È®ÇÑ Áø´ÜÀÌ °¨¿°À» ÁÙÀÌ´Â ¿­¼è°¡ µÉ °ÍÀÔ´Ï´Ù. Ç×±ÕÁ¦ ³»¼º±ÕÀÇ È®»êµµ ½Ã±ÞÇÑ °úÁ¦À̸ç, ¹Î°¨µµ °Ë»ç ¹× ³»¼º À¯ÀüÀÚ °ËÃâÀÌ °¡´ÉÇÑ ºÐ¼®±âÀÇ Çʿ伺ÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO), Áúº´ÅëÁ¦¿¹¹æ¼¾ÅÍ(CDC) µî ¼¼°è ÀÌ´Ï¼ÅÆ¼ºê´Â Áø´Ü ´É·ÂÀ» °¨¿°º´ ´ëÀÀÀÇ Áß¿äÇÑ ÃàÀ¸·Î °­Á¶Çϰí ÀÖ½À´Ï´Ù. ³ó¾÷°ú ½Äǰ »ý»ê¿¡¼­µµ Àμö°øÅëÀü¿°º´ ÀüÆÄ¿¡ ´ëÇÑ ¿ì·Á·Î ÀÎÇØ µ¿¹° À§»ý ¹× ½Äǰ °ø±Þ¸Á¿¡¼­ º´¿øÃ¼ ½ºÅ©¸®´×À» À§ÇÑ ¹Ì»ý¹° ºÐ¼®±â±âÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¼öÁú °Ë»ç ¹× »ý¹°Å×·¯ ´ëÀÀ°ú °°Àº ȯ°æ ¸ð´ÏÅ͸µ ¿ëµµ´Â ÀÌ·¯ÇÑ ½Ã½ºÅÛÀÇ ÀÌ¿ë »ç·Ê¸¦ ´õ¿í È®ÀåÇϰí ÀÖ½À´Ï´Ù. ±âÈÄ º¯È­, ¼¼°è À̵¿¼º, µµ½ÃÈ­·Î ÀÎÇØ Áúº´ ÆÐÅÏÀÌ Á¡Á¡ ´õ º¹ÀâÇØÁö´Â °¡¿îµ¥, ¹Ì»ý¹° ºÐ¼®±â´Â °¨¿°¼º À§ÇùÀ» È¿À²ÀûÀ̰í È¿°úÀûÀ¸·Î ¸ð´ÏÅ͸µ, ´ëÀÀ, ºÀ¼âÇÏ´Â µ¥ ÇÊ¿äÇÑ ºÐ¼® Á¤È®µµ¸¦ Á¦°øÇÕ´Ï´Ù.

Àü ¼¼°è ¹Ì»ý¹° ºÐ¼®±â ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

¹Ì»ý¹° ºÐ¼®±â ½ÃÀåÀÇ ¼ºÀåÀº ÇコÄÉ¾î Æ®·»µå, ±â¼ú Çõ½Å, °øÁß º¸°Ç¿¡ ´ëÇÑ ³ë·Â, ±ÔÁ¦ º¯È­ µîÀÇ º¹ÇÕÀûÀÎ ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁý´Ï´Ù. ÁÖ¿ä ¿øµ¿·ÂÀº Àü ¼¼°è °¨¿°º´ ¹ßº´·ü Áõ°¡·Î ÀÎÇØ °Ë»ç½Ç ÀÚ¿øÀÌ ºÎÁ·ÇØÁ® ½Å¼ÓÇÑ Áø´Ü µµ±¸ÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÇコÄÉ¾î ½Ã½ºÅÛÀÌ Á¶±â ¹ß°ß, ½Ç½Ã°£ ¸ð´ÏÅ͸µ, °³ÀÎ ¸ÂÃãÇü Ä¡·á¸¦ ¿ì¼±½ÃÇÏ´Â °¡¿îµ¥, ¹Ì»ý¹° ºÐ¼®±â´Â ÀÌ·¯ÇÑ ¸ñÇ¥¸¦ Áö¿øÇÏ´Â µ¥ ÇÊ¿äÇÑ ¼Óµµ¿Í Á¤È®¼ºÀ» Á¦°øÇÕ´Ï´Ù. »ý¸í°øÇÐ ¹× ¸¶ÀÌÅ©·ÎÇ÷çÀ̵ñ½º°øÇÐÀÇ ¹ß´Þ·Î ¼ÒÇüÀÇ ´Ù±â´É ºÐ¼®±â°¡ °³¹ßµÇ¾î ÇϳªÀÇ ½Ã·á·Î ´Ù¾çÇÑ °Ë»ç¸¦ ¼öÇàÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. Á¦¾à ¹× »ý¸í°øÇÐ ºÐ¾ß¿¡¼­´Â ¾ö°ÝÇÑ Ç°Áú °ü¸® ±ÔÁ¦·Î ÀÎÇØ ¹Ì»ý¹° ¿À¿° °Ë»ç, ¹«±Õ¼º º¸Áõ, ¹ÙÀÌ¿À¹öµç Æò°¡¸¦ Áö¿øÇÏ´Â ºÐ¼®±â¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¤ºÎÀÇ ÀÚ±Ý Áö¿ø°ú ¹Î°ü ÆÄÆ®³Ê½ÊÀ» ÅëÇØ °í¼Òµæ ±¹°¡¿Í ½ÅÈï±¹ ¸ðµÎ¿¡¼­ Áø´Ü ¿ª·®ÀÌ È®´ëµÇ°í ÀÖÀ¸¸ç, °í±Þ ºÐ¼® ½Ã½ºÅÛ ½ÃÀå °³Ã´ÀÌ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °Ë»çÀÇ ºÐ»êÈ­¿Í Point-of-CareÈ­ Ãß¼¼´Â °Ë»ç½Ç ¼öÁØÀÇ Á¤È®µµ¸¦ À¯ÁöÇϸ鼭 È޴뼺°ú »ç¿ë ÆíÀǼºÀ» °®Ãá ÀåºñÀÇ ±â¼ú Çõ½ÅÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿À» Áß½ÉÀ¸·Î Àü ¼¼°èÀûÀ¸·Î ÀÇ·á Á¢±Ù¼ºÀÌ °³¼±µÊ¿¡ µû¶ó Áø´Ü ÀÎÇÁ¶ó ¹× Àåºñ Á¶´Þ¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå È®´ë¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °¡Ä¡ ±â¹Ý ÀÇ·á¿Í ¾÷¹« È¿À²¼º¿¡ ´ëÇÑ °­Á¶·Î ÀÎÇØ ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü´Â Àüü Áø´Ü ºñ¿ëÀ» ÁÙÀ̸鼭 ½Å·ÚÇÒ ¼ö ÀÖ´Â °á°ú¸¦ Á¦°øÇÏ´Â ÀÚµ¿È­ ½Ã½ºÅÛÀ» µµÀÔÇϰí ÀÖ½À´Ï´Ù. Áø´Ü¾à ±â¾÷ °£ Àü·«Àû Àμö ¹× Á¦ÈÞ¸¦ ÅëÇØ ÅëÇÕ ¼Ö·ç¼ÇÀÇ °³¹ßÀ» °¡¼ÓÈ­Çϰí, Áö¼ÓÀûÀÎ ¿¬±¸°³¹ßÀ» ÅëÇØ °Ë»ç ¸Þ´ºÀÇ È®´ë¿Í ºñ¿ë È¿À²¼ºÀÌ Çâ»óµÉ °ÍÀ¸·Î ±â´ëµË´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ º¹ÇÕÀûÀ¸·Î ÀÛ¿ëÇÏ¿© ¼¼°è ¹Ì»ý¹° ºÐ¼®±â ½ÃÀåÀº °ß°íÇϰí Áö¼ÓÀûÀÎ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç° À¯Çü(ÀÚµ¿ ºÐ¼®±â, ÀÓ»ó ºÐ¼®±â, ºÐÀÚ ºÐ¼®±â, ÀüÀÚµ¿ ºÐ¼®±â), ¿ëµµ(¹Ì»ý¹° °¨¿°Áõ ¿ëµµ, Ç×»ýÁ¦ °¨¼ö¼º ¿ëµµ, ´¢½ºÅ©¸®´× ¿ëµµ, Ç÷¾× ¹è¾ç ¿ëµµ, ±âŸ ¿ëµµ), ÃÖÁ¾ ¿ëµµ(º´¿ø ¹× Áø´Ü¼¾ÅÍ ÃÖÁ¾ ¿ëµµ, Ä¿½ºÅÒ ·¹¹ö·¯Å丮 ¼­ºñ½º Á¦°ø¾÷ü ÃÖÁ¾ ¿ëµµ, Çмú±â°ü ¹× ¿¬±¸±â°ü ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ¼­, ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Microbiology Analyzers Market to Reach US$1.2 Billion by 2030

The global market for Microbiology Analyzers estimated at US$953.2 Million in the year 2024, is expected to reach US$1.2 Billion by 2030, growing at a CAGR of 4.4% over the analysis period 2024-2030. Automated Analyzers, one of the segments analyzed in the report, is expected to record a 3.6% CAGR and reach US$558.6 Million by the end of the analysis period. Growth in the Clinical Analyzers segment is estimated at 3.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$259.7 Million While China is Forecast to Grow at 6.8% CAGR

The Microbiology Analyzers market in the U.S. is estimated at US$259.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$238.0 Million by the year 2030 trailing a CAGR of 6.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.1% and 4.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR.

Global Microbiology Analyzers Market - Key Trends & Drivers Summarized

How Are Microbiology Analyzers Revolutionizing Clinical and Diagnostic Microbiology?

Microbiology analyzers are transforming the way laboratories detect, identify, and monitor microorganisms responsible for infectious diseases, food contamination, and environmental hazards. These automated systems offer rapid, accurate, and high-throughput analysis of bacteria, viruses, fungi, and parasites, reducing the turnaround time that was traditionally required for culture-based methods. In clinical settings, microbiology analyzers play a vital role in diagnosing bloodstream infections, respiratory diseases, urinary tract infections, and hospital-acquired infections by enabling faster pathogen detection and antibiotic susceptibility testing. Advanced analyzers incorporate techniques such as MALDI-TOF mass spectrometry, nucleic acid amplification, and real-time polymerase chain reaction (PCR), which allow laboratories to move beyond basic identification and into genetic characterization of microorganisms. Integration with laboratory information systems (LIS) supports seamless data management, traceability, and reporting, further enhancing operational efficiency. These systems also reduce manual labor and minimize the risk of human error, which is especially critical in high-volume laboratories and outbreak scenarios. Additionally, microbiology analyzers are being increasingly adapted for use in decentralized settings such as clinics, mobile labs, and point-of-care units due to their compact designs and user-friendly interfaces. As antimicrobial resistance (AMR) continues to rise, rapid diagnostic tools like these are becoming indispensable in guiding appropriate therapy and infection control measures. Food safety and pharmaceutical companies are also relying on these systems to meet stringent quality assurance standards by detecting contaminants in raw materials and finished products. With expanding applications and ongoing technological improvements, microbiology analyzers are emerging as a cornerstone in modern diagnostics and public health surveillance.

Why Is the Demand for Automation Driving Innovations in Microbiology Analyzers?

The growing demand for laboratory automation is a major force driving innovation and investment in microbiology analyzers. As laboratories face rising sample volumes, limited staffing, and the need for faster results, automated systems are offering solutions that can process hundreds of samples daily with minimal human intervention. Automation addresses key bottlenecks in traditional microbiology workflows, such as specimen plating, incubation, colony counting, and identification. Sophisticated robotic systems integrated with artificial intelligence and machine learning algorithms now enable real-time image analysis of microbial growth, automatic interpretation of test results, and even predictive analytics for outbreak monitoring. These advancements significantly shorten diagnostic cycles and improve decision-making in critical care scenarios. Fully automated systems not only increase throughput but also ensure consistency and reproducibility, which are vital for clinical accreditation and regulatory compliance. Moreover, next-generation analyzers are designed with modular and scalable features, allowing laboratories to expand capabilities without overhauling existing infrastructure. The standardization of diagnostic processes through automation also helps reduce cross-contamination and improves biosafety in clinical environments. Automation is particularly impactful in resource-constrained settings, where it helps compensate for workforce shortages and improves access to high-quality diagnostics. As hospitals and diagnostic labs adopt lean management principles to optimize efficiency and reduce operational costs, the role of automated microbiology analyzers becomes even more central. The convergence of automation with cloud-based data management and digital connectivity also supports integrated diagnostics and remote result sharing. These developments are not only reshaping laboratory workflows but also creating a new era of rapid, accurate, and data-driven microbial diagnostics.

How Are Emerging Infectious Threats and Global Health Priorities Boosting Market Demand?

The emergence of new infectious diseases and the resurgence of previously controlled pathogens are accelerating global demand for microbiology analyzers. The COVID-19 pandemic underscored the importance of having scalable, reliable, and rapid diagnostic systems that can be deployed in diverse settings. Microbiology analyzers capable of handling molecular and culture-based assays were critical in testing strategies, highlighting their utility in both routine diagnostics and emergency response scenarios. As health systems strengthen surveillance infrastructure to better prepare for future outbreaks, investments in advanced microbiology analyzers have increased across public health laboratories, private clinics, and border control facilities. Diseases such as tuberculosis, influenza, and sexually transmitted infections continue to pose significant health burdens, especially in low- and middle-income countries, where fast and accurate diagnostics are key to reducing transmission. The spread of antimicrobial-resistant organisms is another pressing concern that reinforces the need for analyzers capable of performing susceptibility testing and resistance gene detection. Global initiatives by organizations like the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) have highlighted diagnostic capability as a critical pillar in combating infectious diseases. In agriculture and food production, concerns over zoonotic disease transmission are also driving the adoption of microbiology analyzers for pathogen screening in animal health and food supply chains. Environmental monitoring applications, including water quality testing and bioterrorism preparedness, further expand the use cases for these systems. With disease patterns becoming increasingly complex due to climate change, global mobility, and urbanization, microbiology analyzers offer the analytical precision needed to monitor, respond to, and contain infectious threats efficiently and effectively.

What Factors Are Propelling the Global Growth of the Microbiology Analyzers Market?

The growth in the microbiology analyzers market is driven by a combination of healthcare trends, technological innovation, public health initiatives, and regulatory evolution. A key driver is the global increase in infectious disease incidence, which is straining laboratory resources and heightening the need for rapid diagnostic tools. As healthcare systems prioritize early detection, real-time monitoring, and personalized treatment, microbiology analyzers provide the necessary speed and precision to support these objectives. Advances in biotechnology and microfluidics have led to the development of compact, multi-functional analyzers capable of performing a broad range of tests from a single sample, improving diagnostic yield and reducing sample processing time. In the pharmaceutical and biotechnology sectors, stringent quality control regulations are driving demand for analyzers that support microbial contamination testing, sterility assurance, and bioburden assessments. Furthermore, government funding and public-private partnerships are expanding diagnostic capacity in both high-income and developing nations, facilitating market penetration of sophisticated analyzer systems. The trend toward decentralized and point-of-care testing is also fostering innovation in portable and user-friendly devices that retain laboratory-grade accuracy. As healthcare access improves globally, particularly in Asia-Pacific, Latin America, and the Middle East, there is growing investment in diagnostic infrastructure and equipment procurement, fueling further market expansion. Additionally, the emphasis on value-based care and operational efficiency is encouraging healthcare providers to adopt automated systems that deliver reliable results while reducing overall diagnostic costs. Strategic acquisitions and partnerships among diagnostic companies are accelerating the rollout of integrated solutions, while continued R&D is expected to expand test menus and improve cost-effectiveness. Collectively, these factors are driving robust and sustained growth in the global microbiology analyzers market.

SCOPE OF STUDY:

The report analyzes the Microbiology Analyzers market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Automated Analyzers, Clinical Analyzers, Molecular Analyzers, Fully Automated Analyzers); Application (Microbial Infection Application, Antibiotic Susceptibility Application, Urine Screening Application, Blood Culture Application, Other Applications); End-Use (Hospitals & Diagnostic Centers End-Use, Custom Lab Service Providers End-Use, Academic & Research Institutes End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â